Tango Therapeutics (TNGX) Competitors $3.10 +0.16 (+5.44%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TNGX vs. DAWN, ARDX, SYRE, CALT, SNDX, SPRY, ANIP, RCKT, BCYC, and AVDLShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Calliditas Therapeutics AB (publ) (CALT), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Day One Biopharmaceuticals Ardelyx Spyre Therapeutics Calliditas Therapeutics AB (publ) Syndax Pharmaceuticals ARS Pharmaceuticals ANI Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Tango Therapeutics (NASDAQ:TNGX) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership. Do insiders and institutionals believe in TNGX or DAWN? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Day One Biopharmaceuticals shares are owned by institutional investors. 6.3% of Tango Therapeutics shares are owned by insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer TNGX or DAWN? In the previous week, Day One Biopharmaceuticals had 4 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for Day One Biopharmaceuticals and 0 mentions for Tango Therapeutics. Day One Biopharmaceuticals' average media sentiment score of 0.79 beat Tango Therapeutics' score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Tango Therapeutics Neutral Day One Biopharmaceuticals Positive Do analysts prefer TNGX or DAWN? Tango Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 323.96%. Day One Biopharmaceuticals has a consensus target price of $35.71, indicating a potential upside of 179.24%. Given Tango Therapeutics' higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than Day One Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, TNGX or DAWN? Tango Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.51, indicating that its share price is 251% less volatile than the S&P 500. Is TNGX or DAWN more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to Tango Therapeutics' net margin of -284.42%. Day One Biopharmaceuticals' return on equity of -22.40% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-284.42% -49.64% -32.00% Day One Biopharmaceuticals N/A -22.40%-19.79% Which has stronger valuation and earnings, TNGX or DAWN? Tango Therapeutics has higher earnings, but lower revenue than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$43.38M7.68-$101.74M-$1.18-2.63Day One Biopharmaceuticals$101.95M12.65-$188.92M-$1.03-12.42 Does the MarketBeat Community favor TNGX or DAWN? Day One Biopharmaceuticals received 17 more outperform votes than Tango Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Tango Therapeutics an outperform vote while only 66.18% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformTango TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% Day One BiopharmaceuticalsOutperform Votes4566.18% Underperform Votes2333.82% SummaryDay One Biopharmaceuticals beats Tango Therapeutics on 12 of the 18 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$333.00M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-2.6310.5991.3417.19Price / Sales7.68195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book1.255.104.794.78Net Income-$101.74M$151.51M$120.07M$225.60M7 Day Performance1.31%-2.15%-1.89%-1.24%1 Month Performance-14.60%-3.14%11.45%3.36%1 Year Performance-68.40%11.50%30.61%16.58% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.8423 of 5 stars$3.10+5.4%$13.14+324.0%-68.5%$333.00M$43.38M-2.6390News CoverageHigh Trading VolumeDAWNDay One Biopharmaceuticals1.6299 of 5 stars$12.76+0.1%$35.71+179.9%-7.7%$1.29B$101.95M-12.3860ARDXArdelyx3.6852 of 5 stars$5.38+3.1%$10.42+93.6%-18.9%$1.27B$251.85M-17.80267SYRESpyre Therapeutics1.7682 of 5 stars$24.64+2.2%$51.50+109.0%+53.4%$1.27B$890,000.00-3.23100CALTCalliditas Therapeutics AB (publ)0.0677 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SNDXSyndax Pharmaceuticals3.96 of 5 stars$13.84-0.6%$37.64+171.9%-33.6%$1.18B$16M-3.84110News CoverageSPRYARS Pharmaceuticals2.9441 of 5 stars$12.13+1.9%$24.00+97.9%+121.8%$1.18B$30,000.00-23.3390Insider TradeNews CoverageANIPANI Pharmaceuticals4.8328 of 5 stars$55.89-1.2%$77.71+39.0%+1.9%$1.18B$555.46M-102.89642Insider TradeRCKTRocket Pharmaceuticals4.8035 of 5 stars$11.96-0.5%$51.00+326.4%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.5984 of 5 stars$15.39+11.4%$36.00+133.9%-18.8%$1.06B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6696 of 5 stars$10.94+5.3%$24.43+123.3%-24.0%$1.05B$138.16M-13.15154Positive News Related Companies and Tools Related Companies DAWN Competitors ARDX Competitors SYRE Competitors CALT Competitors SNDX Competitors SPRY Competitors ANIP Competitors RCKT Competitors BCYC Competitors AVDL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNGX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
